The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -61.88 — distress zone — historically elevated failure riskWatch
- Earnings quality 38/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as BioXcel Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Single Reportable$642K
Leadership changes
From BioXcel Therapeutics, Inc.'s own filings, the day they're filed.
- Rajiv Patni · director · appointmenteff. 2025-01-15
- David Mack · director · appointmenteff. 2024-11-21
- Good Reason · departure
Latest filings
- 8-K · Company announcement2026-05-15
- 10-Q · Quarterly report2026-05-15
- 8-K · Company announcement2026-04-17
- 8-K · Company announcement2026-04-01
- 10-K · Annual report2026-03-27
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about BioXcel Therapeutics, Inc., every answer cited🔒
- The Intelligence Brief — added when BioXcel Therapeutics, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.